Updated October 25, 2026 · Sources linked below

A hormone treatment plan should explain more than what will be prescribed. It should state the diagnosis, the intended benefit, the alternatives, and how the clinician will decide whether the plan is working.

Establish the reason for treatment

For men, testosterone therapy should follow an appropriate evaluation for hypogonadism rather than age alone. Symptoms and repeat testing matter, and the cause of deficiency can affect treatment. [1]

For women considering menopause hormone therapy, the discussion depends on symptoms, medical history, treatment route, and personal preferences. The choice between local and systemic treatment is one example of why a single standard package cannot fit everyone. [2]

Define success before treatment starts

A useful goal may be fewer disruptive hot flashes or improvement in a symptom linked to a confirmed deficiency. Ask how progress will be recorded and what a reasonable reassessment period looks like. A laboratory change can inform monitoring without being the only measure of benefit.

Make the safety plan explicit

Discuss relevant contraindications, potential adverse effects, and follow-up testing. Fertility goals are important before testosterone treatment because it can suppress sperm production. [3] Changes in bleeding during menopause care also require clear instructions about when to contact the clinician. [2]

FDA’s 2026 changes to selected menopausal hormone therapy labels should be read accurately: they changed specific boxed warnings, not the need for individual risk assessment. [4]

Before leaving the appointment

  • Can I describe why this treatment is appropriate for me?
  • Do I understand alternatives, including choosing no treatment now?
  • Who should I contact about a problem?
  • When will we reconsider benefits, risks, and the ongoing need for treatment?

Continuity and reassessment are part of treatment quality. A prescription without a clear follow-up plan leaves important decisions unfinished.

Sources and further reading

  1. Endocrine Society: statement on testosterone replacement therapy, 2026
  2. Office on Women’s Health: hormone therapy safety
  3. Endocrine Society: hypogonadism in men
  4. FDA: menopausal hormone therapy labeling changes, February 12, 2026

Patient education from OlympusMD Wellness in Milton, Georgia. This article provides general information and does not replace an individual medical evaluation.